Arterial blood pressure target values in the light of the SPRINT trial results Review article

Article Sidebar

Requires Subscription PDF (Język Polski)


Published: Nov 28, 2016
Keywords:
arterial hypertension, J curve, blood pressure target values, hypotensive therapy

Main Article Content

Jarosław Góra
Klinika Chorób Wewnętrznych, Nadciśnienia Tętniczego i Angiologii, Warszawski Uniwersytet Medyczny, Samodzielny Publiczny Centralny Szpital Kliniczny w Warszawie

Abstract

Reduction of mortality and cardiovascular events rate is the main aim of the antihypertensive treatment. There is an ongoing discussion on the target blood pressure values and the J curve phenomenon, which is an increase of the cardiovascular events associated with low arterial pressure. Several clinical trials on this issue were published recently, including one that was of particular interest – a SPRINT trial. The authors of this study reported an increased risk of cardiovascular events and death in the group with target systolic blood pressure of less than 140 mmHg, compared with the target of less than 120 mmHg. After a detailed analysis of the study protocol and results doubts are expressed about its final interpretation and conclusions.

Downloads

Download data is not yet available.

Article Details

How to Cite
Góra , J. (2016). Arterial blood pressure target values in the light of the SPRINT trial results. Cardiology in Practice, 10(2), 41-44. Retrieved from https://journalsmededu.pl/index.php/kwp/article/view/1286
Issue
Vol 10 No 2 (2016)
Section
Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)

References

1. Tykarski A., Narkiewicz K., Gaciong Z. et al.: Zasady postępowania w nadciśnieniu tętniczym – 2015 rok. Nadciśnienie Tętnicze w Praktyce 2015; 1(1): 1-70.
2. Sleight P., Redon J., Verdecchia P. et al.: Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. J. Hypertens. 2009; 27(7): 1360-1369.
3. Stewart I.M.: Relation of reduction in pressure to first myocardial infarction in patients receiving treatment for severe hypertension. Lancet 1979; 1(8121): 861-865.
4. Cruickshank J.M., Thorp J.M., Zacharias F.J.: Benefits and potential harm of lowering high blood pressure. Lancet 1987; 1(8533): 581-584.
5. D’Agostino R.B., Belanger A.J., Kannel W.B. et al.: Relation of low diastolic blood pressure to coronary heart disease death in presence of myocardial infarction: the Framingham Study. BMJ 1991; 303(6799): 385-389.
6. Lewington S., Clarke R., Qizilbash N. et al.: Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360(9349): 1903-1913.
7. Zanchetti A., Liu L., Mancia G. et al.: Blood pressure and low-density lipoprotein-cholesterol lowering for prevention of strokes and cognitive decline: a review of available trial evidence. J. Hypertens. 2014; 32(9): 1741-1750.
8. MacMahon S., Peto R., Cutler J. et al.: Blood pressure, stroke, and coronary heart disease. Part 1. Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335(8692): 765-774.
9. Group A.S., Cushman W.C., Evans G.W. et al.: Effects of intensive blood-pressure control in type 2 diabetes mellitus. N. Engl. J. Med. 2010; 362(17): 1575-1585.
10. Group S.P.S.S., Benavente O.R., Coffey C.S. et al.: Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet 2013; 382(9891): 507-515.
11. Mancia G., Kjeldsen S.E., Zappe D.H. et al.: Cardiovascular outcomes at different on-treatment blood pressures in the hypertensive patients of the VALUE trial. Eur. Heart J. 2015; 37(12): 955-964. 12. Kjeldsen S.E., Berge E., Bangalore S. et al.: No evidence for a J-shaped curve in treated hypertensive patients with increased cardiovascular risk: The
VALUE trial. Blood Press. 2016; 25(2): 83-92.
13. Group S.R., Wright J.T. Jr., Williamson J.D. et al.: A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N. Engl. J. Med. 2015; 373(22): 2103-2116.
14. Kjeldsen S.E., Narkiewicz K., Hedner T. et al.: The SPRINT study: Outcome may be driven by difference in diuretic treatment demasking heart failure and study design may support systolic blood pressure target below 140 mmHg rather than below 120 mmHg. Blood Press. 2016; 25(2): 63-66.
15. Myers M.G., Godwin M., Dawes M. et al.: Measurement of blood pressure in the office: recognizing the problem and proposing the solution. Hypertension 2010; 55(2): 195-200.
16. Cushman W.C., Whelton P.K., Fine L.J. et al.: SPRINT Trial Results: Latest News in Hypertension Management. Hypertension 2016; 67(2): 263-265.
17. Touyz R.M., Dominiczak A.F.: Successes of SPRINT, but Still Some Hurdles to Cross. Hypertension 2016; 67(2): 268-269.
18. Jones D.W., Weatherly L., Hall J.E.: SPRINT: What Remains Unanswered and Where Do We Go From Here? Hypertension 2016; 67(2): 261-262.
19. Mancia G.: The SPRINT Trial. Cons. Online: http://www.acc.org/latest-in-cardiology/articles/2015/12/01/10/04/the-sprint-trial-cons.